[Multicenter, randomized, positive-controlled clinical study for the effects of nerotropin on diabetic neuropathy].

OBJECTIVE: To estimate the effects of Neurotropin in the treatment of neuralgia and numbness in type 2 diabetes mellitus patients with diabetic peripheral neuropathy (DPN), and compare with Methycobal. METHODS: Ninety-five patients with DPN from 4 hospitals in shanghai were randomly assigned to two groups: 49 cases in Neurotropin group (6 ml, IV, QD for 2 weeks, then, 2 tablets, BID for another 2 weeks). 46 cases in Methycobal group (1 ml, IM, QD for 2 weeks, then, 1 tablet TID for another 2 weeks. RESULTS: Neurotropin significantly improved neuralgia in type 2 diabetes mellitus with DPN, the efficacy rate was 67.3% in the first week, and 87.0% in the 4th week, comparing with 34.8% and 68.5% in the control group. The efficacy rate for numbness was 58.7% in the study group after 4 weeks therapy, and 69.5% in control group. In the whole 4 weeks therapeutic course, neuralgia and numbness were improved in the two groups, and the improved rate in Neurotropin group is high than in the control group (P < 0.01). CONCLUSION: Neurotropin had good effects in the treatment of diabetic neuralgia and numbness, the efficacy of Neurotropin in improving the senses of neuralgia is better than Methecobal., and similar with Methecobal in treating numbness.